ORIGINAL ARTICLE |
|
Year : 2022 | Volume
: 35
| Issue : 1 | Page : 104-109 |
|
The role of serum microRNA-192 for early diagnosis of hepatitis C virus-related hepatocellular carcinoma
Ehab Abd-Elatty1, Elsayed Elshayeb1, Dalia Abou El-Ela2, Mohamed Hamdy1, Lobna AbdEl-Salam3, Hany Abu Zeid Ismail4
1 Department of Internal Medicine, Faculty of Medicine, Menoufia University, Menoufia, Egypt 2 Department of Clinical Pathology, Faculty of Medicine, Menoufia University, Menoufia, Egypt 3 Department of Clinical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt 4 Department of Internal Medicine, Al-Ahrar Teaching Hospital, Sharkia, Egypt
Correspondence Address:
Hany Abu Zeid Ismail Menia El-Kamh, Sharkia Egypt
Source of Support: None, Conflict of Interest: None | Check |
DOI: 10.4103/mmj.mmj_287_20
|
|
Objectives
To elucidate the serum level of microRNA (miRNA)-192 in hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC).
Background
Early diagnosis of HCC presents a challenge owing to lack of reliable biomarkers, stressing the need for new early diagnostic tools. The identification of new high-sensitivity and high-specificity markers for HCC is essential. We aimed to identify serum miRNA-192 as a biomarker to be used in diagnosing HCV-related HCC.
Patients and methods
We investigated serum miRNA-192 expression in 40 patients with HCC, 40 HCV-infected patients, and 20 healthy controls. An initial screening of miRNA-192 expressions by Illumina sequencing was performed using serum samples pooled from patients with HCC, HCV-infected patients, and controls. Quantitative reverse-transcriptase PCR was used to evaluate the expression of miRNA-192. Demographic, radiological, and laboratory analyses were recorded.
Results
MiRNA-192 was significantly increased in HCC group in comparison with HCV and control groups, with cutoff level of 62.06.
Conclusion
MiRNA-192 could be used as a diagnostic biomarker for early detection of HCC in HCV-related cirrhosis, as it showed significant upregulation in patients with HCC in comparison with non-HCC patients.
|
|
|
|
[FULL TEXT] [PDF]* |
|
|
|